Lovastatin indications and usage: Difference between revisions
(Created page with "__NOTOC__ {{Lovastatin}} {{CMG}}; {{AE}} {{SS}} ==Indications and Usage== ===INDICATIONS AND USAGE=== Therapy with lipid-altering agents should be one component of multiple...") |
|||
| Line 5: | Line 5: | ||
==Indications and Usage== | ==Indications and Usage== | ||
Therapy with lipid-altering agents should be one component of multiple risk factor intervention in individuals who require modifications of their lipid profile. Drug therapy is recommended as an adjunct to a diet restricted in saturated fat and [[cholesterol]] only when the response to diet and other non-pharmacological measures has been inadequate. | |||
===Prevention of Coronary Heart Disease=== | |||
In patients without symptomatic [[coronary heart disease]] ([[CHD]]), but at high risk, Altoprev® is indicated to reduce the risk of: | |||
[[Myocardial infarction]] | |||
[[Unstable angina]] | |||
Myocardial infarction | |||
Unstable angina | |||
Coronary revascularization procedures | Coronary revascularization procedures | ||
Coronary Heart Disease | [[Coronary Heart Disease]] | ||
Altoprev® is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. | Altoprev® is indicated to slow the progression of coronary [[atherosclerosis]] in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. | ||
===Hyperlipidemia=== | |||
Altoprev® is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary [[hypercholesterolemia]] (heterozygous familial and non-familial) and mixed [[dyslipidemia]] (Fredrickson types IIa and IIb). | |||
===Limitations of Use=== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher = | date = | accessdate = 13 February 2014 }}</ref> | Altoprev® has not been studied in Fredrickson Types I, III, and V.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher = | date = | accessdate = 13 February 2014 }}</ref> | ||
==References== | ==References== | ||
Revision as of 23:52, 13 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications and Usage
Therapy with lipid-altering agents should be one component of multiple risk factor intervention in individuals who require modifications of their lipid profile. Drug therapy is recommended as an adjunct to a diet restricted in saturated fat and cholesterol only when the response to diet and other non-pharmacological measures has been inadequate.
Prevention of Coronary Heart Disease
In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of:
Myocardial infarction Unstable angina Coronary revascularization procedures
Coronary Heart Disease Altoprev® is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels.
Hyperlipidemia
Altoprev® is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).
Limitations of Use
Altoprev® has not been studied in Fredrickson Types I, III, and V.[1]
References
- ↑ "ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.]". Retrieved 13 February 2014.